- Tabernero, J., Hoff, P. M., Shen, L., Ohtsu, A., Shah, M. A., Siddiqui, A., . . . Kang, Y. K. (2022). Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial. Gastric Cancer. https://doi.org/10.1007/s10120-022-01335-4 (En premsa)
Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial
on 24 d'octubre de 2022
with No hi ha comentaris
Deixa un comentari